The Europe human papillomavirus (HPV) vaccine market is expected to grow from US$ 1,202.66 million in 2022 to US$ 1,598.81 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2022 to 2028.
Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is driving the market. In women, cervical cancer is the fourth most common cancer. In addition, as per the report, titled “Human Papillomavirus and Related Diseases Report-Europe,” in 2020, 8,449 women and 4,327 men had anal cancer in Europe. Such a high incidence rate of HPV-associated infections is favoring the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe human papillomavirus (HPV) vaccine market. The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
Europe Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)
Europe Human Papillomavirus (HPV) Vaccine Market Segmentation
The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022. Based on dosage, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022. Based on age, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022. Based on application, the Europe human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022. Based on end user, the Europe human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022. Based on country, the Europe human papillomavirus (HPV) vaccine market has been categorized into the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe. Germany would dominate the market in 2022.
2A Pharma; ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,202.66 Million |
| Market Size by 2028 | US$ 1,598.81 Million |
| CAGR (2022 - 2028) | 4.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Human Papillomavirus (HPV) Vaccine Market is valued at US$ 1,202.66 Million in 2022, it is projected to reach US$ 1,598.81 Million by 2028.
As per our report Europe Human Papillomavirus (HPV) Vaccine Market, the market size is valued at US$ 1,202.66 Million in 2022, projecting it to reach US$ 1,598.81 Million by 2028. This translates to a CAGR of approximately 4.9% during the forecast period.
The Europe Human Papillomavirus (HPV) Vaccine Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Human Papillomavirus (HPV) Vaccine Market report:
The Europe Human Papillomavirus (HPV) Vaccine Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Human Papillomavirus (HPV) Vaccine Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Human Papillomavirus (HPV) Vaccine Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Human Papillomavirus (HPV) Vaccine Market
